GT Biopharma, Inc. (GTBP) — Dilution Risk Analysis

Current Snapshot

GT Biopharma, Inc. (GTBP) has a DilutionWatch score of 55/10 and is classified as HIGH risk. The score date in the source data is 2026-10-03T03:45:52.527348.

This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.

Share Structure

Shares Outstanding
45,109,497 Source
Public Float
33,531,649 Source
Float as % of Outstanding
74.3%

Dilution Risk Score

Score: 55/10 Source (as of 2026-10-03T03:45:52.527348)

Recent SEC Filings

1 shelf registration or ATM offering filing detected in recent history.

Recent filing forms in the source payload: S-1 2, XBRL 2, 424B3 1, EFFECT 1.

FormFiledAccession
S-1 2026-04-30 0001493152-26-020697
xbrl 2026-04-30 xbrl-6765-xbrl_warrant
424B3 2026-01-30 0001493152-26-004547
EFFECT 2026-01-30 9999999995-26-000420
S-1 2026-01-21 0001493152-26-003089
xbrl 2022-12-31 xbrl-6765-xbrl_convertible

Dilution Risk Drivers

DriverStored ValueSource
Cash runway 13 months Source
Three-year share count growth 2622.75% Source

DilutionWatch Analysis

Risk Level
HIGH (Score: 55/10) Source
Cash Runway
13 months Source
Share Count Growth (3-Year)
2622.75% Source

What This Page Does Not Estimate

DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.

Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.